CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include 15-cubic foot and 30-cubic foot V-shell blenders, a 43-station high speed tablet press, high speed encapsulation and a 40-inch solvent-capable coating pan. The additional equipment train will allow for increased clinical batch sizes in support of growing client demand.  The additional equipment will allow CoreRx scientists to manufacture batch sizes of up to one million solid dosage units per day.

CoreRx, fast becoming a world-recognized leader in early drug contract development, was announced today as one of Tampa Bay’s Fast 50  companies. The Tampa Bay Business Journal’s Fast 50 is a list of the  fastest growing privately held companies in Tampa Bay over a span of  three years. Last year, CoreRx was recognized as the  6th fastest growing company in the Tampa Bay region.

CoreRx continues to grow in 2010, providing unsurpassed contract pharmaceutical development services to the pharma & biotech industries. This is more evident with the latest announcement of the Tampa Bay Business Journal announcement of the Fast 50 nominees.

SoluBest, Ltd, today announced an agreement to license its proprietary nanotechnology platform for significantly improving the bio-performance of poorly soluble and insoluble drugs to CoreRx, Inc., an innovative contract formulation company. SoluBest’s Solumer™ technology is extremely versatile, as it can be applied to a wide range of pharmaceuticals. The license agreement will provide CoreRx with access to Solumer™ technology and the rights to apply the technology to client’s drug candidates currently in clinical development.